[CYTOGEN LOGO]


COMPANY CONTACT:
Cytogen Corporation
Stacy Shearer
Investor Relations
(609) 750-8289
sshearer@cytogen.com
- --------------------


                    CYTOGEN CORPORATION ANNOUNCES ISSUANCE OF
                          $20.5 MILLION IN COMMON STOCK

PRINCETON,  NJ  (NOVEMBER 7, 2003) -- Cytogen  Corporation  (Nasdaq:  CYTO),  an
oncology-focused  biopharmaceutical  company,  today  announced  that it sold to
certain  institutional  investors an aggregate of 1,863,637 shares of registered
common stock for gross proceeds to the Company of  approximately  $20.5 million.
The purchase price was $11.00 per share and the shares were offered  pursuant to
the Company's effective shelf registration  statement.

Proceeds of the offering will be used primarily for general corporate  purposes,
including sales, marketing and clinical development of marketed products.

ABOUT CYTOGEN CORPORATION

Cytogen  Corporation  of  Princeton,  NJ is a  product-driven,  oncology-focused
biopharmaceutical  company.  Cytogen markets  proprietary and licensed  oncology
products  through its in-house  specialty sales force:  Quadramet(R) (a skeletal
targeting  therapeutic  radiopharmaceutical  for the  relief of pain due to bone
metastases);  ProstaScint(R) (a monoclonal  antibody-based imaging agent used to
image the extent and spread of prostate cancer); and NMP22(R) BladderChek(TM) (a
point-of-care,  in  vitro  diagnostic  test for  bladder  cancer).  Cytogen  has
exclusive U.S. marketing rights to Combidex(R), an ultrasmall  superparamagnetic
iron oxide contrast agent for magnetic  resonance imaging of lymph nodes that is
pending clearance by the U.S. Food and Drug  Administration.  Cytogen's pipeline
comprises  product  candidates  at  various  stages  of  clinical   development,
including  fully human  monoclonal  antibodies and cancer vaccines based on PSMA
(prostate specific membrane antigen) technology,  which was exclusively licensed
from Memorial  Sloan-Kettering  Cancer Center. Cytogen also conducts research in
cellular signaling through its AxCell Biosciences  research division in Newtown,
PA. For more information, please visit the Company's website at www.cytogen.com,
which is not part of this press release.

This press release  contains  certain  "forward-looking"  statements  within the
meaning of the Private Securities  Litigation Reform Act of 1995 and Section 21E
of the Securities Exchange Act of 1934, as amended.  All statements,  other than
statements of  historical  facts,  included in this press release  regarding our
strategy,  future operations,  financial  position,  future revenues,  projected
costs,  prospects,  plans  and  objectives  of  management  are  forward-looking
statements.   The  words  "anticipates,"   "believes,"  "estimates,"  "expects,"
"intends," "may," "plans,"  "projects,"  "will," "would" and similar expressions
are  intended  to  identify   forward-looking   statements,   although  not  all
forward-looking statements contain these identifying words. Such forward-looking


statements  involve  a number  of risks  and  uncertainties  and  investors  are
cautioned not to put any undue reliance on any forward-looking  statement. There
are a number of important  factors that could cause Cytogen's  results to differ
materially  from  those  indicated  by  such  forward-looking   statements.   In
particular,  Cytogen's  business  is subject to a number of  significant  risks,
which  include,  but are not limited  to, the risk of  obtaining  the  necessary
regulatory  approvals,  the risk of whether  products  result  from  development
activities,  the risk of shifts in the regulatory environment affecting sales of
Cytogen's products such as third-party payor reimbursement  issues, and the risk
associated with Cytogen's  dependence on its partners for development of certain
projects. Cytogen cannot guarantee that Cytogen will actually achieve the plans,
intentions or  expectations  disclosed in any such  forward-looking  statements.
Cytogen's actual results may differ materially from Cytogen's historical results
of operations  and those  discussed in such  forward-looking  statements and the
risks stated above for various reasons, including, but not limited to, Cytogen's
ability  to  carry  out  its  business  and  financial  plans,  to  successfully
commercialize Quadramet(R), to determine and implement the appropriate strategic
initiative for its AxCell Biosciences subsidiary,  to fund development necessary
for  existing  products  and to pursue new product  opportunities,  to integrate
in-licensed  products  such  as  NMP22(R)  BladderChek(TM),   to  establish  and
successfully  complete clinical trials where required for product  approval,  to
obtain  foreign  regulatory  approvals  for products and to establish  marketing
arrangements  in  countries  where  approval  is  obtained,  and  other  factors
discussed  in  Cytogen's  Form 10-K for the year ended  December  31,  2002,  as
amended,  and from  time-to-time  in Cytogen's other filings with the Securities
and Exchange Commission.  Any forward-looking  statements made by Cytogen do not
reflect the potential impact of any future acquisitions,  mergers, dispositions,
joint ventures or  investments  Cytogen may make.  Cytogen does not assume,  and
specifically disclaims, any obligation to update any forward-looking statements,
and these  statements  represent  Cytogen's  current outlook only as of the date
given.

                                       ###